Grifols Alzheimer's drug AMBAR shows 61% reduction in disease progression
Grifols strengthened evidence for its AMBAR program with new real-world evidence data showing a 61% reduction in disease progression in patients with mild to moderate Alzheimer's disease compared with untreated patients. The AMBAR protocol is being implemented at hospitals in Spain and discussions are underway with add